Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    "Creutzfeldt-Jakob disease"

The Role of the Coagulation Pathway at the Synapse in Prion Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02480725
Recruitment Status : Not yet recruiting
First Posted : June 24, 2015
Last Update Posted : June 24, 2015
Sponsor:
Collaborator:
Prof. Zerr , Prion Referral Center , University of Gottingen, Germany
Information provided by (Responsible Party):
Dr. Oren Cohen, Sheba Medical Center

Tracking Information
First Submitted Date June 22, 2015
First Posted Date June 24, 2015
Last Update Posted Date June 24, 2015
Study Start Date June 2015
Estimated Primary Completion Date July 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 23, 2015)
Thrombin activity assay [ Time Frame: 10 years ]
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Role of the Coagulation Pathway at the Synapse in Prion Diseases
Official Title The Role of the Coagulation Pathway at the Synapse in Prion Diseases
Brief Summary

The study hypothesis is that that the deleterious effect of prions on the brain may be mediated (at least partially) by activation of serine proteases involved in the coagulation system. If this is true, then measurement of the activity of the coagulation system may be a marker of disease onset (in at higher risk individuals such as E200K* carriers) and for disease progression or activity in affected individuals. In addition, modulation of the coagulation system activity may be a potential tool for therapeutic intervention.

*E200K- E200K mutation (Glu to Lys substitution) in the prion protein gene

Detailed Description

We plan to collect Cerebrospinal fluid (CSF) samples for thrombin activity assay in order to test whether there is a difference in thrombin activity in the CSF between CJD (Creutzfeldt-Jakob disease) and non-CJD patients. CSF samples will be obtained from two sources 1. Patients with familial or sporadic CJD and control patients with other neurodegenerative disorders (e.g. SDAT**, NPH) that will be evaluated in Sheba Medical Center 2. From our collaborating group of Prof. Zerr in the German Prion Referral Center at the University of Gottingen which has a collection of thousands of CSF samples from patients with familial and sporadic CJD as well as ideal controls with other degenerative brain disease.

The study has 2 sections:

  1. Prospective part in which we plan to recruit 25 patients with CJD and 25 patients with other types of dementia from Sheba Medical Center (SMC). Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).

    Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.

    No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.

  2. Retrospective part in which CSF samples from CJD patients and patients with other type of dementia will be shipped to us from our collaborators in Germany ans will be assayed for Thrombin activity. We plan to recruit to this part of the study 100-200 CJD patient CSF samples and a same number of samples from age matched controls.

Thrombin activity (for samples from both parts of the study) will be assayed as follows: CSF sample will be placed in a black 96 well dish (10 per well). Thrombin activity will be measured by a fluorometric assay, quantifying the cleavage of the synthetic peptide substrate Boc-Asp(OBzl)-Pro-Arg-AMC*** (I-1560, Bachem, Switzerland, 13 molar final concentration). Measurements will be performed by the Infinite 2000 microplate reader (Tecan, infinite 200, Switzerland) with excitation and emission filters of 360±35 and 460±35 nm, respectively. CSF testing for thrombin activity will be conducted in Professor Chapman's laboratory in Sheba. This laboratory is actively engaged in research on the role of thrombin and PAR-1 in diseases of the nervous system and is fully equipped to perform the biochemical and protein levels experiments.

The assay has the potential for commercialization as a diagnostic test for CJD. In addition, there is the potential to develop therapeutic agents targeting excessive thrombin activation.

**SDAT=Senile Dementia of Alzheimer Type

***AMC= Amino Methyl Coumarin

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
CSF samples
Sampling Method Non-Probability Sample
Study Population CJD and non-CJD patients
Condition Creutzfeldt-Jakob Syndrome
Intervention Procedure: collect CSF (Cerebrospinal fluid) sample
collecting CSF samples for thrombin activity assay
Study Groups/Cohorts
  • CJD (Creutzfeldt-Jakob disease) patients

    Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).

    Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.

    No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.

    We plan to collect CSF samples for thrombin activity assay.

  • non-CJD patients with a type of dementia

    Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).

    Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.

    No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.

    We plan to collect CSF samples for thrombin activity assay.

    Intervention: Procedure: collect CSF (Cerebrospinal fluid) sample
  • CSF samples of non-CJD patient used as control
    CSF samples : Thrombin activity will be assayed.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: June 23, 2015)
50
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2025
Estimated Primary Completion Date July 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patient undergoing lumbar puncture test as part of the investigation of cognitive decline.

Exclusion Criteria:

  • Patients on anticoagulation or those who have contraindication for undergoing lumbar puncture.
Sex/Gender
Sexes Eligible for Study: All
Ages 35 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Oren Cohen, Dr. (MD) +972-52-6667584 coheno@asaf.health.gov.il
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT02480725
Other Study ID Numbers 1702-14 SMC
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Dr. Oren Cohen, Sheba Medical Center
Study Sponsor Sheba Medical Center
Collaborators Prof. Zerr , Prion Referral Center , University of Gottingen, Germany
Investigators
Principal Investigator: Oren Cohen, Dr. (MD) Cheba Medical Center
PRS Account Sheba Medical Center
Verification Date June 2015